GSK Taiwan Please tell our readers about the importance of GSK Taiwan within the context of the company’s global operations, and also what there is in Taiwan that makes it so attractive for GSK. The Asia Pacific region for GSK consists of South East Asia, Korea, Taiwan and Australia. Due to being…
Taiwan Intellectual property Office Please explain the factors that led to the creation of the Taiwan Intellectual Property Office, and its main activities today. For the Taiwanese government, intellectual property (IP) rights are very important, as they are one of the key factors to attracting foreign investment. As a result, for a number of…
Daiichi Sankyo France When we met your Italian colleague, he noted that they had tripled their turnover in a five year period. You haven’t done badly yourself in the relatively short period of time you’ve been present in the Market. Is this a European-wide phenomenon for Daiichi Sankyo or is there something special…
Eisai France Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France going to bridge the gap between this blockbuster and the other developments that are coming down the pipeline? In regard…
Paion Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company we see today? The reason for founding Paion in 2000 was more a question of timing of our own development.…
Minister for Health How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since the introduction of the national health insurance system in 1977, the Korean national healthcare system has been experiencing dramatic growth, guaranteeing healthcare to every…
AIFA When you were appointed General Director of the Agenzia Italiana del Farmaco (AIFA) in 2007, the dedicated Investigation Commission highlighted the need for an in-depth reorganization of the Agency in order to create a more cohesive and transparent structure- which implied significant changes in the main six macro-areas and the…
Daiichi Sankyo Italy When you became President of Sankyo Pharma Italy in 2003 one of your objectives was to maximize sales of the existing portfolio- and the company’s sales have impressively tripled in this 5 years period. What have been the main guidelines of the Italian operations? Daiichi Sankyo Italy’s ability to brilliantly…
Thailand Thailand might already have become a medical tourism destination but the country still needs to sort out serious issues on its local market as the country healthcare system is largely underfunded, the country depends on imported drugs and APIs, local companies are lagging behind in terms of manufacturing practices and…
See our Cookie Privacy Policy Here
